Efficacy and safety of aripiprazole in child and adolescent patients

European Child and Adolescent Psychiatry

Volumn 21, Issue 7, 2012, Pages 361-368

  Kirino, Eiji ^a,b  

^a JUNTENDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

Author keywords

ADHD; Adolescent; Aripiprazole; Asperger's syndrome; Child; Pervasive development disorder

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; PLACEBO; RISPERIDONE; SEROTONIN RECEPTOR;

ADOLESCENT; AGGRESSION; AGITATION; AKATHISIA; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; BINDING AFFINITY; BIPOLAR I DISORDER; BIPOLAR MANIA; BODY WEIGHT; CHILD; DELUSIONAL DISORDER; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; INSOMNIA; METABOLIC DISORDER; METABOLIC PARAMETERS; OBSESSIVE COMPULSIVE DISORDER; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRESYNCOPE; PROLACTIN BLOOD LEVEL; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; TIC; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; BIPOLAR DISORDER; CHILD; HUMANS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 84865115422     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-012-0270-0     Document Type: Review

References (46)

1. Kikuchi T (2007) The research and development of aripiprazole and its mechanism of action. Jpn J Clin Psychopharmacol 10(3):464-468
2. Stahl SM (2001) Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 62(12):923-924 (Pubitemid 34007955)
3. Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T et al (2005) Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 515(1-3):10-19 (Pubitemid 40779262)
4. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E et al (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60(7):681-690 (Pubitemid 36818630)
5. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998) Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl) -N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry (Clinical Trial Controlled Clinical Trial Research Support, U.S. Gov't, P.H.S.) 43(1):2-11 (Pubitemid 28059067)
6. Tamminga CA, Carlsson A (2002) Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 1(2):141-147
7. Tamminga CA (2002) Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109(3):411-420
8. Olbrich R, Schanz H (1991) An evaluation of the partial dopa-mine agonist terguride regarding positive symptoms reduction in schizophrenics. J Neural Transm Gen Sect. (Clinical Trial) 84(3): 233-236
9. Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21(6):389-390 (Pubitemid 19024195)
10. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharma-cology 28(8):1400-1411 (Pubitemid 41070874)
11. Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH et al (1998) Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci USA 95(25):15049-15054 (Pubitemid 29003754)
12. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27(7):1159-1172 (Pubitemid 37464960)
13. DeBattista C, Hawkins J (2009) Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 23(5):369-377
14. Fernandez HH, Trieschmann ME, Friedman JH (2004) Aripip-razole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 27(1):4-5 (Pubitemid 38280379)
15. de Quervain DJ, Henke K, Aerni A, Coluccia D, Wollmer MA, Hock C et al (2003) A functional genetic variation of the 5-HT2a receptor affects human memory. Nat Neurosci 6(11):1141-1142 (Pubitemid 37346032)
16. Grunder G, Kungel M, Ebrecht M, Gorocs T, Modell S (2006) Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 39(Suppl 1):S21-S25 (Pubitemid 43357102)
17. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H et al (2004) Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psycho-pharmacol 18(3):375-383 (Pubitemid 39382565)
18. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wir-shing WC (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63(10):856-865 (Pubitemid 35231725)
19. Sargent PA, Sharpley AL, Williams C, Goodall EM, Cowen PJ (1997) 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133(3):309-312 (Pubitemid 27445666)
20. Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13(1):27-35 (Pubitemid 350275185)
21. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.) 28(3):519-526
22. Goodnick PJ, Jerry JM (2002) Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 3(12):1773-1781 (Pubitemid 36054598)
23. Stahl SM, Shayegan DK (2003) The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 64(Suppl 19):6-12
24. Bolden C, Cusack B, Richelson E (1992) Antagonism by an-timuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther (Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.) 260(2):576-580
25. Shayegan DK, Stahl SM (2004) Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 9(10 Suppl 11):6-14 (Pubitemid 39473434)
26. Davies MA, Sheffler DJ, Roth BL (2004) Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 10(4):317-336 (Pubitemid 40128915)
27. American Psychiatric Association (2004) Practice guideline for the treatment of patients with schizophrenia, 2nd edn. American Psychiatric Association, Arlington (VA)
28. Sanford M, Keating GM (2007) Aripiprazole: in adolescents with schizophrenia. Paediatr Drugs 9(6):419-423 (Pubitemid 350208916)
29. Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P et al (2007) An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 12(9):683-689 (Pubitemid 47571968)
30. Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T et al (2009) Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 70(10):1441-1451
31. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD et al (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124(6):1533-1540
32. Robb AS, Carson WH, Nyilas M, Ali M, Forbes RA, Iwamoto T et al (2010) Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data. J Child Adolesc Psychopharmacol 20(1):33-38
33. Aparasu RR, Bhatara V (2007) Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin 23(1):49-56 (Pubitemid 46191669)
34. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S et al (2008) A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165(11):1432-1441
35. Kirino E (2010) Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. Clin Schizophr Relat Psychoses 4(3):185-188
36. Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA (2009) Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 70(5):756-764
37. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH et al (2009) A placebo-controlled, fixed-dose study of ari-piprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48(11):1110-1119
38. Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ et al (2009) Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 19(3):265-274
39. Masi G, Cosenza A, Millepiedi S, Muratori F, Pari C, Salvadori F (2009) Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 23(6):511-521
40. Findling RL, Short EJ, Leskovec T, Townsend LD, Demeter CA, McNamara NK et al (2008) Aripiprazole in children with atten-tion-deficit/hyperactivity disorder. J Child Adolesc Psychophar-macol 18(4):347-354
41. Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY (2007) An open-label study of the efficacy and tolerability of aripip-razole for children and adolescents with tic disorders. J Clin Psychiatry 68(7):1088-1093 (Pubitemid 47340331)
42. Seo WS, Sung HM, Sea HS, Bai DS (2008) Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 18(2):197-205 (Pubitemid 351591440)
43. Myers WC, Ruiz R (2004) Aripiprazole and psychotherapy for delusional disorder, erotomanic type. J Am Acad Child Adolesc Psychiatry 43(9):1069-1070 (Pubitemid 39096863)
44. Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK (2008) Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 25(2):172-174 (Pubitemid 351341964)
45. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302(16):1765-1773
46. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70(Suppl 4):1-46 (quiz 7-8)